Health
RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
Johnson & Johnson (NYSE:JNJ) today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor (EGFR) and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer. The encouraging anti-tumor activity, durable responses, and low rates of treatment-related discontinuations observed in this study support further
About this update from Johnson & Johnson
[{"type":"text","content":"Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months","length":142,"tagName":"p"},{"type":"text","content":"Notable responses were also seen in patients with liver metastases, who often face poorer outcomes with this disease","length":116,"tagName":"p"},{"type":"text","content":"RARITAN, N.J., Jan. 10, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor (EGFR) and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer. The encouraging anti-tumor activity, durable responses, and low rates of treatment-related discontinuations observed in this study support further investigation in ongoing Phase 3 studies in first- and second-line colorectal cancer. Results were presented during a poster session at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium (Abstract #166).1","length":799,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Johnson & Johnson)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Johnson & Johnson)","className":"","disableSlideshowImg":false,"size":{"original":{"width":1280,"height":720,"url":"https://mma.prnewswire.com/media/2333578/Johnson_and_Johnson_Logo.jpg"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LydLS8mq.UQ.hdlrVWoWzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://mma.prnewswire.com/media/2333578/Johnson_and_Johnson_Logo.jpg","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/hx0ruTYcJT59RbqDBDdPeA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUwO2NmPXdlYnA-/https://mma.prnewswire.com/media/2333578/Johnson_and_Johnson_Logo.jpg","width":1200,"height":675}},"href":"https://mma.prnewswire.com/media/2333578/Johnson_and_Johnson_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""These results show the potential of amivantamab combined with chemotherapy to deliver meaningful and durable benefit for people with advanced colorectal cancer, including for those with liver metastases who have historically faced poorer outcomes," said Dr. Fi...